Blog

  • PM calls for transforming PNSC to meet int’l standards – RADIO PAKISTAN

    1. PM calls for transforming PNSC to meet int’l standards  RADIO PAKISTAN
    2. PM directs for comprehensive plan to elevate PNSC to int’l standards  Ptv.com.pk
    3. Prime Minister Muhammad Shehbaz Sharif chairs a meeting on PNSC  Associated Press of Pakistan
    4. PM Shehbaz calls for transforming PNSC to meet int’l standards  SUCH TV
    5. PM Wants to Transform PNSC Into International-Standard Shipping Company  ProPakistani

    Continue Reading

  • Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

    Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease

    CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax®, the Company’s COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. The Company’s COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization (EUA).

    “COVID-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We appreciate the FDA’s diligent scientific review and approval of Spikevax for pediatric populations at increased risk for COVID-19 disease.”

    Moderna expects to have its updated Spikevax vaccine available for eligible populations in the U.S. for the 2025-2026 respiratory virus season.

    About Moderna

    Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.

    Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.

    Spikevax® is a registered trademark of Moderna.

    INDICATION

    SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine to protect you against COVID-19. SPIKEVAX is for people who are:

    • 65 years of age and older, or

    • 6 months through 64 years of age at high risk for severe COVID-19.

    Vaccination with SPIKEVAX may not protect all people who receive the vaccine.

    IMPORTANT SAFETY INFORMATION

    You or your child should not get SPIKEVAX if you had a severe allergic reaction after a previous dose of SPIKEVAX or any Moderna COVID-19 vaccine or to any ingredient in these vaccines.

    What are the risks of SPIKEVAX?

    There is a very small chance that SPIKEVAX could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to 1 hour after getting a dose of SPIKEVAX. For this reason, the healthcare provider may ask you or your child to stay for a short time at the place where you or your child received your vaccine. Signs of a severe allergic reaction can include:

    • Trouble breathing

    • Swelling of your face and throat

    • A fast heartbeat

    • A rash all over your body

    • Dizziness and weakness

    • Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received mRNA COVID-19 vaccines. Myocarditis and pericarditis following mRNA COVID-19 vaccines have occurred most commonly in males 12 years through 24 years of age. You should seek medical attention right away if you or your child has any of the following symptoms after receiving Spikevax, particularly during the 2 weeks after receiving a dose of the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart. Additional symptoms in children may include fainting, irritability, poor feeding, lack of energy, vomiting, pain in the abdomen, or cool, pale skin.

    Other side effects that have been reported include:

    • Injection site reactions: pain, tenderness and swelling of the lymph nodes in the same arm of the injection or in the groin, swelling (hardness), and redness

    • General side effects: fatigue, headache, muscle pain, joint pain, chills, nausea and vomiting, fever, rash, irritability/crying, sleepiness, and loss of appetite.

    • Fainting and febrile seizures (convulsions during a fever) were also reported

    Tell the healthcare provider about all of your or your child’s medical conditions, including if you or your child:

    • have any allergies

    • had a severe allergic reaction after receiving a previous dose of any COVID-19 vaccine

    • have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart)

    • have a fever

    • have a bleeding disorder or are on a blood thinner

    • are immunocompromised or on a medicine that affects your immune system

    • are pregnant or plan to become pregnant

    • are breastfeeding

    • have received any other COVID-19 vaccine

    • have ever fainted in association with an injection

    These may not be all the possible side effects of SPIKEVAX. Ask your healthcare provider about any side effects that concern you. You may report side effects to Vaccine Adverse Event Reporting System (VAERS) at 1-800-822-7967 or http://vaers.hhs.gov.

    Please see the SPIKEVAX Full Prescribing Information.

    Moderna Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the availability of an updated Spikevax vaccine for eligible populations in the U.S. for the 2025-2026 respiratory virus season. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date of this press release.

    Moderna Contacts

    Media:
    Chris Ridley
    Head of Global Media Relations
    +1 617-800-3651
    [email protected]

    Investors:
    Lavina Talukdar
    Senior Vice President & Head of Investor Relations
    +1 617-209-5834
    [email protected]

    SOURCE: Moderna, Inc.

    Continue Reading

  • OpenAI and Perplexity Browsers Revolutionising Web

    OpenAI and Perplexity Browsers Revolutionising Web

    Google’s Chrome accounts for around two thirds of web browsing globally, well ahead of rivals like Apple’s Safari and Microsoft’s Edge. Its next challenge appears to be coming from the biggest beasts of the AI world. Reuters reported that OpenAI is preparing to launch an ‘AI-powered web browser’ in the coming weeks which is “designed to keep some user interactions within a ChatGPT-like native chat interface instead of clicking through to websites”. That’s delightful news for website owners, of course.

    Meanwhile, Perplexity – another of the big AI firms – has just unveiled an AI-powered browser called Comet. “A shift from browsing to thinking,” is the pitch here. “Comet transforms entire browsing sessions into single, seamless interactions, collapsing complex workflows into fluid conversations…” For now, it’s only available to subscribers to the company’s Perplexity Max tier, which costs $200 a month.


    Continue Reading

  • The 9 best creator-approved gadgets on sale during Prime Day

    The 9 best creator-approved gadgets on sale during Prime Day

    Perhaps nobody understands the tools needed to navigate the modern world better than creators. They’re the folks who need to create content quickly, on the go, and still make it look beautiful enough for long-form YouTube content. They need to be able to snap a wonderful picture for Instagram or record a POV video for TikTok at a moment’s notice.

    It makes sense, then, that you’d want to take an influencer’s recommendation for tech gadgets. After all, who would have more experience? So, that’s exactly what we’ve been doing in advance of Prime Day 2025.

    Mashable recently launched an entire series called In My Bag in which creators reveal the essential tools of their trade. Relying on that series, and our own considerable knowledge of the tech space, we’ve combed through Amazon’s Prime Day deals to find the best discounts on creator-approved, must-have gadgets.

    A smartphone gimbal stabilizer

    Mashable Tech Editor Timothy Werth has been testing this newly released DJI phone gimbal for iPhones, and he’s been impressed by how easy it is to use. (Yes, it works with Android devices, too.) These smartphone tripods and stabilizers adjust in real time to provide professional-quality footage from your smartphone. Even though DJI just released this smartphone gimbal in 2025, it’s gotten a Prime Day price drop to $129.

    The Alix Earle light

    Uber-popular influencer Alix Earle first made this clip-on selfie light viral, which is actually called the Newmowa 60-LED High-Power Selfie Light. It’s easy to comprehend why creators love this little light. It’s convenient — you can clip it onto your phone, computer, or just about anything else — and it immediately provides powerful, flattering lighting. And at $23.99, that’s the lowest-ever price for the light on Amazon.

    A drone perfect for creators

    Creators often need stellar aerial shots, and the DJI Neo mini drone is certainly capable of that. The compact, lightweight drone is discounted by $60 this Prime Day. For a very decent price, your videos could take a major step up. This mini drone offers 4K video and can launch from the palm of your hand — no piloting license required.

    An on-the-go tripod from Joby

    The Joby GorillaPod tripod was a favorite when we spoke with tech creators at VidCon 2025. It’s discounted 15% for Prime Day, priced at $59.48. It’s a durable, compact tripod that lets you attach your camera to just about anything, just about anywhere. It’s perfect for content creators who might need to shoot at a moment’s notice.

    A SanDisk hard drive to store all your footage

    A hard drive might not be the most fun purchase, but it is eminently usable. (These drives always go on sale for Prime Day.) Creators, especially, need to have storage available at all times. SanDisk’s 1TB Extreme Portable hard drive is 40% off, priced at $77.99 for Amazon’s 2025 Prime Day. That’s a solid deal on a very practical piece of tech.

    The Sony camera designed to vlog

    Sony designed this camera specifically for vloggers and creators, and it’s discounted $100 at Best Buy, a solid deal you won’t find at Amazon. The ZV-1 has lots of features that are appealing for creators, such as WiFi capability, image stabilization, different shooting modes (such as portrait or night), and a flippable screen that allows you to see your shot in real time.

    A suction-cup phone mount from Octobuddy

    Not every gadget has to be fancy. Sometimes you just need a suction-cup-clad phone mount so you can slap your device on a wall and film. The Octobuddy phone mount, a silicone pad with the aforementioned suction cups, is a favorite among creators for its simplicity and reliability.

    Mashable Deals

    “[My] most essential tool is [the] Octobuddy phone mount, which lets me film almost anywhere” food creator Tess Gigone told Mashable for our In My Bag series. “Most of my videos happen in my kitchen, where I attach my phone to the window in front of me.”

    The Octobuddy is priced at $11.99 for Prime Day, a 20% discount.

    A discounted Canon camera

    It’s 2025 and creators increasingly need high-quality footage to do their jobs. The Canon EOS R100 promises 4K footage while still remaining light and relatively affordable. It’s 16% off for Amazon’s Prime Day, priced at $549. It should provide everything a creator needs — especially those just getting started — while not totally breaking the bank like other cameras.

    A podcasting mic

    In our Starter Kit series, we talked to experts about all the best tools needed to launch a podcast, and that definitely includes the Blue Yeti USB microphone. For Prime Day, you can pick up this popular podcasting and livestreaming microphone for under $100 at Amazon.


    Best Curated Amazon Prime Day Deals

    Products available for purchase here through affiliate links are selected by our merchandising team. If you buy something through links on our site, Mashable may earn an affiliate commission.


    Continue Reading

  • MRI findings of confluent hepatic fibrosis caused by different etiologies | BMC Gastroenterology

    MRI findings of confluent hepatic fibrosis caused by different etiologies | BMC Gastroenterology

    In this study, we performed a comparative analysis of clinical data and MRI findings of CHF across patients with different underlying causes. Patients with CHF had a median age of 55 years, with 68% being female. Most CHF lesions were distributed near the second hepatic hilum, predominantly revealing radial and wedge-shaped patterns, and delayed enhancement on contrast-enhanced MRI. Most CHF lesions showed hypointensity on T1WI, while they appeared mild to moderate hyperintense on T2WI, DWI, and ADC maps. The CHF lesions were often accompanied by obvious liver cirrhosis and capsular retraction.

    In our study, drug-induced liver injury and autoimmune hepatitis predominated among liver diseases, a finding partially consistent with prior research [15]. However, Ohtomo et al. reported that viral hepatitis was the primary etiology of liver cirrhosis, which led to a larger proportion (14%) of CHF in their study [4]. Therefore, we suppose that the differences of study subjects and enrolled patients make the results deviate. The patients with primary sclerosing cholangitis had a relatively small sample size in our study, which limited further comparison.

    It is well-known that males are more susceptible to alcoholic liver disease and chronic hepatitis B [16], consistent with our findings. Our study also showed that the drug-induced liver injury group was predominantly composed of older females. Bilaj et al. reported that in their study, six CHF lesions were found in 32 patients with autoimmune hepatitis [17]. It is known that autoimmune hepatitis can lead to chronic liver disease. Notably, our study found a higher proportion of younger females among autoimmune hepatitis patients, in line with other research [18].

    In terms of location and morphology, our findings indicated that CHF lesions predominantly appeared as patches, radially distributed around the second hepatic hilum, and were primarily located in the left medial lobe and right anterior lobe. These two lobes are within the drainage area of the middle hepatic vein (MHV). The MHV has a shorter length, smaller proximal diameter and larger drainage flow, which may lead to higher retro-sinusoidal pressure from regenerating nodules [19]. However, some lesions also showed diffuse distribution around the vascular structures and beneath the hepatic capsule. Histopathological examination typically revealed an abundance of macrophages, as well as varying degrees of hepatocyte necrosis, and increased steatosis [20]. Some CHF lesions exhibited a cord-like shape, suggesting end-stage of fibrosis. As the lesions showed more extensive confluent patterns, their size increased. When multiple lesions of CHF were present, they showed a focal distribution pattern and uneven thickness, with these characteristics occurring in specific areas of the liver rather than being diffusely distributed throughout the entire liver. While the imaging of diffuse fibrosis revealed a reticular pattern of fine fibrotic bands that were slightly hyperintense on the fat-suppressed T2WI sequence, with homogeneous thickness and delayed enhancement. Regenerative nodules were observed within these fibrotic bands [21].

    On conventional MRI, most lesions exhibited low T1WI signal and mild to moderate hyperintensity on T2WI, without hemorrhage or cystic areas, consistent with previous studies [22]. In DWI sequences, CHF showed slightly restricted diffusion, with ADC values higher than the surrounding liver parenchyma, suggesting potential collagen bundle loosening within the lesions [23]. This distinct pattern may help differentiate CHF from infiltrative HCC, which typically exhibits lower ADC values [24].

    On the late arterial phase, approximately half of CHF lesions showed mild-to-moderate enhancement, indicating immature fibrosis with significant inflammatory infiltration on microscopy [25]. On the portal venous phase, most CHF lesions exhibited high signal enhancement. On the delayed phase, all CHF lesions demonstrated predominantly uniform high signal, suggesting fibrosis characteristics. These features help to differentiate CHF from non-neoplastic lesions such as vascular hepatic perfusional changes. The typical manifestations of vascular hepatic perfusional changes display patchy areas with relatively hypo-enhancement or hyper-enhancement observed on the arterial phase, and appeared isointense on the portal venous phase or delayed phase compared with the surrounding normal hepatic parenchyma with blood vessels running through [26]. Hepatobiliary contrast agents provide no significant advantage over conventional agents, as both CHF and many neoplastic lesions typically show low signal in the hepatobiliary phase due to absence of functioning hepatocytes [27, 28].

    In terms of accompanied findings, most cases showed obvious liver cirrhosis with capsular retraction, also observed in other liver diseases [29]. The degree of capsular retraction correlated with cirrhosis progression [30]. Early fibrosis appears as patches, while advanced fibrosis presents as patches and streaks near the liver capsule, leading to retraction and volume loss. Additionally, some livers of our patients had smooth borders, suggesting potential differences in CHF mechanisms between hepatitis and cirrhosis. Further research is needed to explore this.

    Based on previous literatures, the diagnosis of CHF should be differentiated from infiltrative HCC and ICC. Infiltrative HCC lesions typically exhibit imaging features such as significant nonrim arterial phase hyperenhancement, wash-out on portal venous or delayed phase, a lower ADC value, satellite nodules, and the formation of tumor thrombus within the portal vein [31, 32]. In contrast, CHF lesions show no or mild-moderate enhancement on the arterial phase, hyperenhancement on the delayed phase relative to the background parenchyma, as well as hepatic volume loss, slightly narrowed intrahepatic vessels, but no tumor thrombus. ICC lesions usually present as target masses, with rim arterial phase hyperenhancement, peripheral washout, delayed central enhancement, targetoid restriction on DWI and ADC map, and associate with capsule contraction at the periphery and distal bile duct dilation [33]. Early-stage CHF lesions may show no or mild-moderate enhancement on the arterial phase, lack capsule contraction, and have a relatively high ADC value. These key imaging discriminators can guide clinical decisions, such as avoiding biopsy for typical CHF or performing a biopsy if the enhancement pattern is atypical.

    Building on the preceding discussion and in accordance with the Liver Imaging Reporting and Data System version (LI-RADS) v2018 [34], we recommend the following MRI sequences for evaluating CHF: T1WI in-phase and out-of-phase, T2WI, DWI, late arterial phase, portal venous phase, and delayed phase enhanced imaging. If feasible, the hepatobiliary phase and magnetic resonance elastography can also be included.

    This study has several limitations. First, its retrospective, single-center design introduced inherent selection bias. Additionally, the sample size particularly in subgroup analyses was insufficient, which may have biased the results. Variations in MRI scanners and contrast agents could have contributed to image heterogeneity. Furthermore, the lack of biopsy for pathological confirmation in CHF cases may have resulted in misclassification bias. Future studies should include a larger, more diverse cohort to address these limitations.

    Continue Reading

  • Azma Bokhari denounces fake news, defends CM Maryam’s governance

    Azma Bokhari denounces fake news, defends CM Maryam’s governance



    Pakistan


    Says no audit report questioned Maryam Nawaz’s tenure; accuses PTI of funds misuse. propaganda





    LAHORE (Dunya News) – Punjab Information Minister Azma Bokhari has criticised what she termed a “fitna (anarchy) group” for spreading propaganda and fake news, clarifying that no audit report has so far raised questions about the tenure of Chief Minister Maryam Nawaz.

    At a press conference in Lahore, Bokhari emphasised that transparency is the hallmark of Maryam Nawaz’s administration.

    She accused the former PTI-led Punjab government of misusing funds by stockpiling wheat in the name of farmers while profiting from the reserves.

    She further stated that the province has seen a rapid decline in crime, with the “Dala culture” (referring to VIP culture) being eliminated. The performance of Punjab’s CCD (Criminal Control Division) is being widely praised on social media, she noted, quoting the Chief Minister’s commitment that no criminal would be allowed to roam freely.

    Addressing political tensions, Bokhari challenged the PTI founder to bring his daughter into the political discourse and warned that disruption in the name of politics would not be tolerated.

    More to read: Yousuf Raza Gilani acquitted in nine more TDAP corruption cases

    “Pakistan Tehreek-i-Insaf has nothing better to do and constantly fabricates stories,” she said, adding that PTI-affiliated YouTubers even incited conflict during the India-Pakistan war narrative.

    She also addressed misinformation regarding the reported meeting between US President Donald Trump and Field Marshal Syed Asim Munir, which she claimed was distorted by PTI for political mileage.

    Concluding her remarks, Bokhari commended the Punjab government’s arrangements during Muharram, highlighting the religious harmony shown by all sects. She also shared that a delegation recently awarded CM Maryam Nawaz a Peace Award for her efforts in maintaining public order. 

    ‘ ;
    var i = Math.floor(r_text.length * Math.random());
    document.write(r_text[i]);

    Continue Reading

  • ANP leader Maulana Khan Zeb, cop gunned down in KP’s Bajaur: police – Pakistan

    ANP leader Maulana Khan Zeb, cop gunned down in KP’s Bajaur: police – Pakistan

    Awami National Party (ANP) politician Maulana Khan Zeb and a policeman were shot dead on Thursday by unidentified suspects in Khyber Pakhtunkhwa’s Bajaur district, according to the police.

    Bajaur District Police Officer (DPO) Waqas Rafiq told Dawn.com that the politician was shot dead in Shindai Mor while campaigning for the July 13 peace parade, adding that a policeman was also killed in the attack.

    “Three other people were injured in the shooting,” DPO Rafiq said. “This was a targeted killing carried out by unidentified shooters on motorcycles.”

    DPO Rafiq added that evidence had been collected from the crime scene.

    Khan Zeb was a member of the ANP’s central cabinet and held the office of secretary of ulema affairs, according to the party website.

    ANP President Senator Aimal Wali Khan issued a statement condemning the killing, stating that the party would file a first information report against the state.

    “State institutions are complicit in this incident because they have maintained criminal silence,” the ANP chief was quoted as saying. “After consulting with Khan Zeb’s elder brother, Sheikh Jahanzada, an FIR for the killing will be registered against the state.”

    In a post on X, Wali Khan posted photos of himself and Khan Zeb with the caption “devastated”.

    Meanwhile, ANP KP President Mian Ifitkhar Hussain strongly condemned the incident and declared three days of mourning in a statement shared on X.

    “This attack is not only an attack on the Awami National Party but also on the Pashtun consciousness and peace,” Hussain was quoted as saying.

    According to the statement, Hussain announced that the ANP’s KP chapter would observe three days of mourning, suspend all activities, and hoist black flags alongside party flags.

    The statement added that Hussain was leaving for Bajaur and urged the party to maintain “morale, unity, and organisational discipline”.

    Similarly, the office of KP Chief Minister Ali Amin Gandapur issued a statement condemning the incident and vowed to bring the suspects to justice.

    According to the statement, the CM condemned the shooting and ordered the relevant authorities to investigate the incident and promptly arrest the shooters.

    “Those involved in the incident will not be able to escape the grip of the law,” Gandapur was quoted as saying.

    Politicians in KP have been targeted in attacks in the past.

    This year, the home of Bajaur MNA Mubarak Zeb Khan was attacked twice, with an improvised explosive device exploding outside his house in May and suspects launching a rocket at the residence in June.

    He was not home during the IED attack and was unharmed in the second incident.

    Meanwhile, in March, the brother of former Jamaat-i-Islami (JI) senator Mushtaq Ahmad Khan was shot dead in KP’s Swabi.

    The former senator confirmed on social media that his elder brother, Shakeel Ahmad Khan, was shot dead in front of his house by unidentified gunmen in the village of Ahad Khan in Swabi.

    “He was brutally killed in front of his home in an innocent village,” Mushtaq wrote. “My brother was very dear to me, he was my greatest help. It (his murder) is the greatest atrocity.”


    Additional reporting by Zahid Imdad

    Continue Reading

  • This chipmaker is catching up to Nvidia and can soar 45%, HSBC says

    This chipmaker is catching up to Nvidia and can soar 45%, HSBC says

    Continue Reading

  • EastEnders and theatre actor Frank Barrie dies aged 88

    EastEnders and theatre actor Frank Barrie dies aged 88

    Theatre star and former EastEnders actor Frank Barrie has died aged 88.

    The Scarborough-born performer passed away peacefully at home surrounded by family, his agency Scott Marshall Partners said.

    Barrie, who grew up in York, played Dot Cotton’s love interest Edward Bishop in EastEnders from 2010 to 2011.

    He was also known for his numerous Shakespearean roles on stage and was a member of Sir Laurence Olivier’s National Theatre Company at the Old Vic.

    The statement from his agency read: “It is with great sadness that we announce the death of our beloved client, Frank Barrie, at the age of 88.

    “He died peacefully at home, with his wife Mary and daughter Julia.”

    Barrie attended Archbishop Holgate’s School in York, before going to the University of Hull where he met his wife.

    He made his acting debut at York Theatre Royal in 1959, in a production of Henry IV Part 2.

    The actor went on to star in The Woman In Black and Lunch With Marlene, and his one-man show Macready! played in 65 countries.

    Barrie also made more than 150 screen appearances, including in shows such as Emergency Ward 10, No Hiding Place, Softly, Softly, Special Branch, On Giant’s Shoulders and Queen Of Swords.

    In 1983, he played Eglamour in the BBC TV adaptation of Shakespeare’s The Two Gentlemen Of Verona.

    He also found success as a director on productions of Shylock, JM Barrie and The Life And Loves Of Edith Wharton, all of which toured internationally.

    Continue Reading

  • WHO warns of infectious disease surge among deported Afghan migrants amid poor sanitary conditions – ANI News

    1. WHO warns of infectious disease surge among deported Afghan migrants amid poor sanitary conditions  ANI News
    2. Iran expels half a million Afghans in 16-day stretch since recent conflict with Israel, UN says  CNN
    3. TAWDIKHABARI – Iran’s Mistreatment of Afghan Refugees Discussed  TOLOnews
    4. Iran tells millions of Afghans to leave or face arrest on day of deadline  Al Jazeera
    5. WHO warns of rising spread of infectious diseases among deported Afghan migrants, calls for increasing medical resources  Tribune India

    Continue Reading